Synopsis
Synopsis
0
EU WC
0
KDMF
0
VMF
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-4-piperidinecarboxylic Acid
2. Bilina
3. Lvophta
4. Levocabastine
5. Levophta
6. Livocab
7. Livostin
1. Levocabastine Hcl
2. Livostin
3. 79547-78-7
4. Livostin (tn)
5. R 50,547
6. 124xma6yei
7. Levocabastine (hydrochloride)
8. Levophta
9. (-)-trans-1-(cis-4-cyano-4-(p-fluorophenyl)cyclohexyl)-3-methyl-4-phenylisonipecotic Acid Monohydrochloride
10. Dsstox_cid_25508
11. Dsstox_rid_80921
12. Dsstox_gsid_45508
13. R-50547
14. (3s,4r)-1-((1s,4r)-4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenylpiperidine-4-carboxylic Acid Hydrochloride
15. Levocabastine Hydrochloride [usan]
16. Unii-124xma6yei
17. (3s,4r)-cabastine Hydrochloride
18. Levocabastine Hydrochloride [usan:usp]
19. Ncgc00016939-01
20. Cas-79547-78-7
21. Schembl99969
22. Schembl99970
23. Mls002154116
24. Chembl1237102
25. Dtxsid9045508
26. Chebi:31777
27. Hms1571o19
28. Tox21_110695
29. Hy-14277a
30. Levocabastine Hydrochloride (jan/usp)
31. Tox21_110695_1
32. At25912
33. Ccg-221039
34. Levocabastine Hydrochloride [jan]
35. Ncgc00179240-04
36. 4-piperidinecarboxylic Acid, 1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-, Monohydrochloride, (-)-(1(cis),3alpha,4beta)-
37. 4-piperidinecarboxylic Acid, 1-(cis-4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-, Monohydrochloride, (3s,4r)-
38. Smr001233423
39. Levocabastine Hydrochloride [mart.]
40. Levocabastine Hydrochloride [vandf]
41. Levocabastine Hydrochloride [usp-rs]
42. Levocabastine Hydrochloride [who-dd]
43. Cs-0031223
44. D01717
45. Levocabastine Hydrochloride [ep Impurity]
46. Levocabastine Hydrochloride [orange Book]
47. Levocabastine Hydrochloride [ep Monograph]
48. Levocabastine Hydrochloride [usp Impurity]
49. Levocabastine Hydrochloride [usp Monograph]
50. Levocabastine Hydrochloride, >=99% (hplc), Solid
51. Q27251370
52. Levocabastine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
53. Levocabastine For System Suitability 2, European Pharmacopoeia (ep) Reference Standard
54. Levocabastine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
55. (3s,4r)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic Acid;hydrochloride
56. 4-piperidinecarboxylic Acid, 1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-, Monohydrochloride, (-)-(1(cis),3.alpha.,4.beta.)-
Molecular Weight | 457.0 g/mol |
---|---|
Molecular Formula | C26H30ClFN2O2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 4 |
Exact Mass | 456.1979841 g/mol |
Monoisotopic Mass | 456.1979841 g/mol |
Topological Polar Surface Area | 64.3 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 681 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Histamine H1 Antagonists, Non-Sedating
A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment. (See all compounds classified as Histamine H1 Antagonists, Non-Sedating.)
Certificate Number : R1-CEP 2012-002 - Rev 04
Status : Valid
Issue Date : 2021-11-16
Type : Chemical
Substance Number : 1484
Certificate Number : R1-CEP 2002-147 - Rev 03
Status : Valid
Issue Date : 2020-12-09
Type : Chemical
Substance Number : 1484
Levocabastine Hydrochloride, Process Part 2
Certificate Number : CEP 2018-217 - Rev 01
Status : Valid
Issue Date : 2024-09-02
Type : Chemical
Substance Number : 1484
Certificate Number : R1-CEP 2014-277 - Rev 00
Status : Valid
Issue Date : 2021-10-27
Type : Chemical
Substance Number : 1484
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
72
PharmaCompass offers a list of Levocabastine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Levocabastine manufacturer or Levocabastine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Levocabastine manufacturer or Levocabastine supplier.
PharmaCompass also assists you with knowing the Levocabastine API Price utilized in the formulation of products. Levocabastine API Price is not always fixed or binding as the Levocabastine Price is obtained through a variety of data sources. The Levocabastine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Bilina manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bilina, including repackagers and relabelers. The FDA regulates Bilina manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bilina API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Bilina manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Bilina supplier is an individual or a company that provides Bilina active pharmaceutical ingredient (API) or Bilina finished formulations upon request. The Bilina suppliers may include Bilina API manufacturers, exporters, distributors and traders.
click here to find a list of Bilina suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Bilina DMF (Drug Master File) is a document detailing the whole manufacturing process of Bilina active pharmaceutical ingredient (API) in detail. Different forms of Bilina DMFs exist exist since differing nations have different regulations, such as Bilina USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Bilina DMF submitted to regulatory agencies in the US is known as a USDMF. Bilina USDMF includes data on Bilina's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Bilina USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Bilina suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Bilina Drug Master File in Japan (Bilina JDMF) empowers Bilina API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Bilina JDMF during the approval evaluation for pharmaceutical products. At the time of Bilina JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Bilina suppliers with JDMF on PharmaCompass.
A Bilina CEP of the European Pharmacopoeia monograph is often referred to as a Bilina Certificate of Suitability (COS). The purpose of a Bilina CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Bilina EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Bilina to their clients by showing that a Bilina CEP has been issued for it. The manufacturer submits a Bilina CEP (COS) as part of the market authorization procedure, and it takes on the role of a Bilina CEP holder for the record. Additionally, the data presented in the Bilina CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Bilina DMF.
A Bilina CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Bilina CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Bilina suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bilina as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Bilina API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Bilina as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Bilina and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Bilina NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Bilina suppliers with NDC on PharmaCompass.
Bilina Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bilina GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bilina GMP manufacturer or Bilina GMP API supplier for your needs.
A Bilina CoA (Certificate of Analysis) is a formal document that attests to Bilina's compliance with Bilina specifications and serves as a tool for batch-level quality control.
Bilina CoA mostly includes findings from lab analyses of a specific batch. For each Bilina CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bilina may be tested according to a variety of international standards, such as European Pharmacopoeia (Bilina EP), Bilina JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bilina USP).